Publication: Modificación de mecanismos asociados a la patogénesis y evolución de aneurismas de aorta abdominal mediante inhibición del factor Xa con rivaroxabán
Loading...
Files
Official URL
Full text at PDC
Publication Date
2021-11-25
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Complutense de Madrid
Citations
Exportar
Abstract
El aneurisma de aorta abdominal (AAA) sigue siendo una de las causas más importantes de mortalidad en el mundo occidental, llegando a ser la decimoquinta causa de muerte global. Actualmente no existe ninguna terapia médica efectiva para la prevención y tratamiento de los AAA. Sin embargo, los mecanismos etiopatogénicos de la enfermedad han sido ampliamente estudiados y se conoce el papel fundamental de la actividad proteolítica, la inflamación y el estrés oxidativo en la formación, desarrollo y rotura delos AAA. El factor Xa (FXa) es uno de los componentes más importantes de la cascada de la coagulación, pero también presenta efectos directos sobre la pared vascular alterando el metabolismo energético y aumentando el estrés oxidativo y la inflamación a dicho nivel. El rivaroxabán, un inhibidor del FXa, ha demostrado tener efectos antiinflamatorios y antiestrés oxidativo en enfermedades que comparten factores etiopatogénicos con los AAA, tales como la ateroesclerosis. No obstante, no se ha estudiado aún el efecto de este fármaco en AAA humanos...
Abdominal aortic aneurysms (AAA) remain one of the leading mortality causes in western countries, being the fifteenth most common cause of death globally. No effective medical therapy is currently available for the prevention and treatment of AAA. However, the etiopathogenesis of this disease has been thoroughly studied and it is well known the key role of proteolytic activity, inflammation and oxidative stress in the development, growth and rupture of AAAs. Factor Xa (FXa) is one of the most important components of the coagulation cascade, but it also has a direct effect on the vascular wall, modifying the energetic metabolism and increasing the oxidative stress and inflammation at that level. Rivaroxaban, a FXa inhibitor, has proved to have anti-inflammatory and anti-oxidative stress effects in diseases that share pathogenic mechanisms with AAAs, such as atherosclerosis. However, the effect of this drug in human AAAs has not been assessedyet...
Abdominal aortic aneurysms (AAA) remain one of the leading mortality causes in western countries, being the fifteenth most common cause of death globally. No effective medical therapy is currently available for the prevention and treatment of AAA. However, the etiopathogenesis of this disease has been thoroughly studied and it is well known the key role of proteolytic activity, inflammation and oxidative stress in the development, growth and rupture of AAAs. Factor Xa (FXa) is one of the most important components of the coagulation cascade, but it also has a direct effect on the vascular wall, modifying the energetic metabolism and increasing the oxidative stress and inflammation at that level. Rivaroxaban, a FXa inhibitor, has proved to have anti-inflammatory and anti-oxidative stress effects in diseases that share pathogenic mechanisms with AAAs, such as atherosclerosis. However, the effect of this drug in human AAAs has not been assessedyet...
Description
Tesis inédita de la Universidad Complutense de Madrid, Facultad de Medicina, leída el 13-07-2021